Literature DB >> 20629184

Modulation of neutrophil motility by curcumin: implications for inflammatory bowel disease.

C B Larmonier1, M T Midura-Kiela, R Ramalingam, D Laubitz, N Janikashvili, N Larmonier, F K Ghishan, P R Kiela.   

Abstract

BACKGROUND: Neutrophils (PMN) are the first cells recruited at the site of inflammation. They play a key role in the innate immune response by recognizing, ingesting, and eliminating pathogens and participate in the orientation of the adaptive immune responses. However, in inflammatory bowel disease (IBD) transepithelial neutrophil migration leads to an impaired epithelial barrier function, perpetuation of inflammation, and tissue destruction via oxidative and proteolytic damage. Curcumin (diferulolylmethane) displays a protective role in mouse models of IBD and in human ulcerative colitis, a phenomenon consistently accompanied by a reduced mucosal neutrophil infiltration.
METHODS: We investigated the effect of curcumin on mouse and human neutrophil polarization and motility in vitro and in vivo.
RESULTS: Curcumin attenuated lipopolysaccharide (LPS)-stimulated expression and secretion of macrophage inflammatory protein (MIP)-2, interleukin (IL)-1β, keratinocyte chemoattractant (KC), and MIP-1α in colonic epithelial cells (CECs) and in macrophages. Curcumin significantly inhibited PMN chemotaxis against MIP-2, KC, or against conditioned media from LPS-treated macrophages or CEC, a well as the IL-8-mediated chemotaxis of human neutrophils. At nontoxic concentrations, curcumin inhibited random neutrophil migration, suggesting a direct effect on neutrophil chemokinesis. Curcumin-mediated inhibition of PMN motility could be attributed to a downregulation of PI3K activity, AKT phosphorylation, and F-actin polymerization at the leading edge. The inhibitory effect of curcumin on neutrophil motility was further demonstrated in vivo in a model of aseptic peritonitis.
CONCLUSIONS: Our results indicate that curcumin interferes with colonic inflammation partly through inhibition of the chemokine expression and through direct inhibition of neutrophil chemotaxis and chemokinesis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20629184      PMCID: PMC2958245          DOI: 10.1002/ibd.21391

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  55 in total

Review 1.  Small molecule antagonists of the CXCR2 and CXCR1 chemokine receptors as therapeutic agents for the treatment of inflammatory diseases.

Authors:  Jakob Busch-Petersen
Journal:  Curr Top Med Chem       Date:  2006       Impact factor: 3.295

2.  Curcumin for maintenance therapy in ulcerative colitis.

Authors:  Alan C Moss
Journal:  Clin Gastroenterol Hepatol       Date:  2007-05       Impact factor: 11.382

3.  Curcumin, a Curcuma longa constituent, acts on MAPK p38 pathway modulating COX-2 and iNOS expression in chronic experimental colitis.

Authors:  Laura Camacho-Barquero; Isabel Villegas; Juan Manuel Sánchez-Calvo; Elena Talero; Susana Sánchez-Fidalgo; Virginia Motilva; Catalina Alarcón de la Lastra
Journal:  Int Immunopharmacol       Date:  2006-12-18       Impact factor: 4.932

4.  Curcumin-attenuated trinitrobenzene sulphonic acid induces chronic colitis by inhibiting expression of cyclooxygenase-2.

Authors:  Hua Jiang; Chang-Sheng Deng; Ming Zhang; Jian Xia
Journal:  World J Gastroenterol       Date:  2006-06-28       Impact factor: 5.742

Review 5.  "Spicing up" of the immune system by curcumin.

Authors:  Ganesh Chandra Jagetia; Bharat B Aggarwal
Journal:  J Clin Immunol       Date:  2007-01-09       Impact factor: 8.317

6.  NCB-02 (standardized Curcumin preparation) protects dinitrochlorobenzene- induced colitis through down-regulation of NFkappa-B and iNOS.

Authors:  M V Venkataranganna; Md Rafiq; S Gopumadhavan; Ghouse Peer; U V Babu; S K Mitra
Journal:  World J Gastroenterol       Date:  2007-02-21       Impact factor: 5.742

Review 7.  Chemokines in the inflammatory bowel diseases.

Authors:  R P MacDermott
Journal:  J Clin Immunol       Date:  1999-09       Impact factor: 8.317

8.  Curcumin inhibits trinitrobenzene sulphonic acid-induced colitis in rats by activation of peroxisome proliferator-activated receptor gamma.

Authors:  Ming Zhang; Changsheng Deng; Jiaju Zheng; Jian Xia; Dan Sheng
Journal:  Int Immunopharmacol       Date:  2006-04-07       Impact factor: 4.932

9.  Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial.

Authors:  Hiroyuki Hanai; Takayuki Iida; Ken Takeuchi; Fumitoshi Watanabe; Yasuhiko Maruyama; Akira Andoh; Tomoyuki Tsujikawa; Yosihihide Fujiyama; Keiichi Mitsuyama; Michio Sata; Masami Yamada; Yasushi Iwaoka; Kazunari Kanke; Hideyuki Hiraishi; Kazuhisa Hirayama; Hajime Arai; Shigehito Yoshii; Masato Uchijima; Toshi Nagata; Yukio Koide
Journal:  Clin Gastroenterol Hepatol       Date:  2006-11-13       Impact factor: 11.382

10.  Efficacy and mechanism of action of turmeric supplements in the treatment of experimental arthritis.

Authors:  Janet L Funk; Jennifer B Frye; Janice N Oyarzo; Nesrin Kuscuoglu; Jonathan Wilson; Gwen McCaffrey; Gregory Stafford; Guanjie Chen; R Clark Lantz; Shivanand D Jolad; Aniko M Sólyom; Pawel R Kiela; Barbara N Timmermann
Journal:  Arthritis Rheum       Date:  2006-11
View more
  30 in total

1.  Sex- and corticotropin-releasing factor receptor 2- dependent actions of urocortin 1 during inflammation.

Authors:  Burcu Hasdemir; Pallavi Mhaske; Sreenivasan Paruthiyil; Elizabeth A Garnett; Melvin B Heyman; Mehrdad Matloubian; Aditi Bhargava
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2016-04-06       Impact factor: 3.619

2.  Curcumin ameliorates dextran sulfate sodium-induced colitis in mice via regulation of autophagy and intestinal immunity.

Authors:  Wenjie Yue; Yi Liu; Xiang Li; Liyuan Lv; Jianping Huang; Jie Liu
Journal:  Turk J Gastroenterol       Date:  2019-03       Impact factor: 1.852

3.  Cannabinoid receptor-2 (CB2) agonist ameliorates colitis in IL-10(-/-) mice by attenuating the activation of T cells and promoting their apoptosis.

Authors:  Udai P Singh; Narendra P Singh; Balwan Singh; Robert L Price; Mitzi Nagarkatti; Prakash S Nagarkatti
Journal:  Toxicol Appl Pharmacol       Date:  2011-11-18       Impact factor: 4.219

4.  Therapeutic potential of curcumin in gastrointestinal diseases.

Authors:  Sigrid A Rajasekaran
Journal:  World J Gastrointest Pathophysiol       Date:  2011-02-15

Review 5.  Advances in treatment of ulcerative colitis with herbs: from bench to bedside.

Authors:  Ping Wan; Hao Chen; Yuan Guo; Ai-Ping Bai
Journal:  World J Gastroenterol       Date:  2014-10-21       Impact factor: 5.742

6.  Protectin DX, a double lipoxygenase product of DHA, inhibits both ROS production in human neutrophils and cyclooxygenase activities.

Authors:  Miao Liu; Tarek Boussetta; Karama Makni-Maalej; Michèle Fay; Fathi Driss; Jamel El-Benna; Michel Lagarde; Michel Guichardant
Journal:  Lipids       Date:  2013-11-20       Impact factor: 1.880

Review 7.  Immunomodulatory Yersinia outer proteins (Yops)-useful tools for bacteria and humans alike.

Authors:  Benjamin Grabowski; M Alexander Schmidt; Christian Rüter
Journal:  Virulence       Date:  2017-03-15       Impact factor: 5.882

8.  Cinnamaldehyde is the main mediator of cinnamon extract in mast cell inhibition.

Authors:  Yvonne Hagenlocher; Kristina Kiessling; Michael Schäffer; Stephan C Bischoff; Axel Lorentz
Journal:  Eur J Nutr       Date:  2014-12-11       Impact factor: 5.614

9.  A Systematic Review of the Clinical Use of Curcumin for the Management of Gastrointestinal Diseases.

Authors:  Masoumeh Atefi; Mina Darand; Mohammad Hassan Entezari; Tannaz Jamialahmadi; Mohammad Bagherniya; Amirhossein Sahebkar
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

10.  The Role of Curcumin in Modulating Colonic Microbiota During Colitis and Colon Cancer Prevention.

Authors:  Rita-Marie T McFadden; Claire B Larmonier; Kareem W Shehab; Monica Midura-Kiela; Rajalakshmy Ramalingam; Christy A Harrison; David G Besselsen; John H Chase; J Gregory Caporaso; Christian Jobin; Fayez K Ghishan; Pawel R Kiela
Journal:  Inflamm Bowel Dis       Date:  2015-11       Impact factor: 5.325

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.